Aarkstore - Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

1
Aarkstore - Ophthalmic Drugs Data, Analysis
and Forecasts to 2024
Category Healthcare
2
Aarkstore - Ophthalmic Drugs Data, Analysis and
Forecasts to 2024
3
Summary

• Which ophthalmic drugs lead the market in 2013?
  Will the same drugs be as successful in 2018? How
  will this landscape change across the next 10
  years? Which trial drugs are likely to make an
  impact? Only one report will tell you the
  answers. Simply by ordering and reading GMR
  Datas new Ophthalmic Drugs Data, Analysis and
  Forecasts to 2024 report, you can stay ahead of
  your competition. It really is that simple.
•  
• GMR Data forecasts that the global ophthalmic
  drugs market will reach 9.7bn by 2024. The US
  market growth will be slow compared to other
  markets predominantly due to major drug patent
  expiry and generic erosion. For example

4
Xalabrands from Pfizer used for treatment of
Glaucoma expired in the US in March 2011. Azopt
by Alcon used for treatment of Glaucoma expired
in the US in October 2012. Lumigan by Allergan
used for treatment of Glaucoma expired in the US
in 2013. Restasis from Allergan used for
treatment of Dry eye will expire in the US in May
2014. Travatan by Alcon used for treatment of
Glaucoma will expire in the US in 2014.
Combigan by Allergan used for treatment of
Glaucoma will expire in the US in 2022.
Lucentis from Novartis used for treatment of
Retinal Disorder will expire in the US in June
2020. Restasis by Allergan is the market-leading
drug in the ophthalmic market with sales of 1bn
across 2013. Will it be able to see off the
competition for the next 5 years? The next 10
years? This report tells you. With an assessment
of the leading markets, such as the US, and EU,
GMR Data examine how Germany and France are the
largest EU markets and what of the global
market they make up. Which other countries
contribute most? This report tells you in a
concise, focused and easily accessible format.
 
5
Table of Contents

• 1. Executive Summary
• 1.1 Ophthalmic Drugs Market Review
• 1.2 Chapter Breakdown
• 1.3 Research and Analysis Methods
• 2. Causes and Treatments of Ophthalmic Disorders
• 2.1 Human Eye
• 2.2 Structure of Human Eye
• 2.3 Major Global Causes of Blindness Vision
  Impairment
• 2.3.1 Primary Causes of Blindness
• 2.3.2 Primary Causes of Visual Impairment
• 2.3.3 Geographic Breakdown of Global Blindness
  and Vision Impairment
• 2.3.4 Primary Factors Contributing to Visual
  Impairment
• 2.4 The Most Common Type of Eye Disorders
• 2.4.1 Cataracts
• 2.4.2 Glaucoma
• 2.4.3 Retinal Detachment
•  

6
List Of Tables

• Table 2.3 WHO Estimation of Blind/Vision impaired
  Population Globally, 1975-2010
• Table 2.3.1 Breakdown of Global Blindness Cases
  as per Eye Disease
• Table 2.3.2 Breakdown of Global Vision Impairment
  Cases as per Eye Disease 2010
• Table 2.4.2.1 Major Glaucoma Drugs in the Market
• Table 2.4.4.1 Major Ophthalmic Anti-allergy Drugs
  in the Market
• Table 2.4.5.1 Major Ophthalmic Anti-inflammatory
  Drugs in the Market
• Table 2.4.6.1 Major Ophthalmic Anti-infective
  Drugs in the Market
• Table 2.4.7.1 Major Diabetic Retinopathy Drugs in
  the Market
• Table 2.4.8.1 Major Dry Eye Treatment Drugs in
  the Market
• Table 2.4.9.1 Major wet-AMD Treatment Drugs in
  the Market

7
List Of Figures

• Figure 2.3 WHO Estimation of Blind/Vision
  impaired Population Globally, 1975-2010
• Figure 2.3.1 Breakdown of Global Blindness Cases,
  as per Eye Disease, 2010
• Figure 2.3.2 Breakdown of Global Vision
  Impairment Cases as per Eye Disease 2010
• Figure 2.3.3 Breakdown of Global Blindness and
  Vision Impairment by Geography 2012
• Figure 2.3.4 Projection of Global Blind People
  aged 50 by 2019
• Figure 3.2.1 Market Size and Forecast Global
  Ophthalmology Pharmaceuticals Sales (/m)
• Figure 3.2.2 Global Ophthalmology Pharmaceuticals
  Drug Market Share 2014 to 2024 ()
• Figure 4.2.1 Population of over 60s in Selected
  Nations 2009 (millions)
• Figure 4.2.2 Market Share of Major Companies by
  Sales of Anti-Glaucoma Drug 2012
•  

8
Related Reports

• Generic Drugs Market in Japan 2015-2019
• Lung Cancer-Global API Manufacturers, Marketed
  and Phase III Drugs Landscape, 2015
• Metastatic Brain Tumor-Global API Manufacturers,
  Marketed and Phase III Drugs Landscape, 2015
• Lupus Erythematosus-Global API Manufacturers,
  Marketed and Phase III Drugs Landscape, 2015
• Metastatic Breast Cancer-Global API
  Manufacturers, Marketed and Phase III Drugs
  Landscape, 2015

9
Related Reports

• Malaria-Global API Manufacturers, Marketed and
  Phase III Drugs Landscape, 2015
• Metastatic Colorectal Cancer-Global API
  Manufacturers, Marketed and Phase III Drugs
  Landscape, 2015
• Melanoma-Global API Manufacturers, Marketed and
  Phase III Drugs Landscape, 2015
• Metastatic Hormone Refractory (Castration
  Resistant, Androgen-Independent) Prostate
  Cancer-Global API Manufacturers, Marketed and
  Phase III Drugs Landscape, 2015
• Pharmaceuticals Healthcare Market Research
  Reports

10
Ophthalmic Drugs Data, Analysis and Forecasts to
2024 Published Sep 2014 160 Pages GMR Data
forecasts that the global ophthalmic drugs market
will reach 9.7bn by 2024.
Format Price
PDF 1799
Site License 3599
Enterprise Wide Licence 8499
11
Contact Us

• Office
• Office No. - 809, 8th Floor,
• B-Wing, Mahaavir Icon, 
• Plot No.- 89 90, Sector-15,
• CBD-Belapur, Navi Mumbai 400614, 
• Maharashtra, India.
• Telefax No 91 22 4127 6660
• 24/7 Online Support 91 9987295242
• General Inquiries 91 - 22 2756 4953

• You Can Visit
• http//www.aarkstore.com
• OR Mail us at
• contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news